Jiyeon Denninger
Medical Director, Clinical Development Sarepta Therapeutics
Jiyeon Denninger is a Medical Director of Clinical Development at Sarepta Therapeutics, where she contributes to the development of innovative therapies for rare neuromuscular diseases. She brings a unique physician-scientist perspective, having earned her MD and PhD from the University of Connecticut and built her career around patient-focused research and drug development. Prior to joining Sarepta, Dr. Denninger conducted research in neuromuscular biology and translational medicine, including postdoctoral work at The Ohio State University, before transitioning into industry. Since joining Sarepta, she has supported the clinical advancement of genetic medicines aimed at addressing significant unmet needs for patients and families affected by rare diseases.
Seminars
- Examining the disconnect between statistical significance and meaningful patient benefit in muscular disorder trials to deliver more tangible improvements for patients
- Assessing emerging functional, digital and patient-centered endpoints alongside conventional measures to focus on treatment effects which are relevant to disease burden
- Defining a clinically meaningful change for patients, clinicians and regulators to collaboratively guide endpoint selection and increase confidence in development outcomes
- Leveraging genetic, molecular and disease-specific biomarkers to distinguish patient subgroups within Duchenne, Becker, FSHD, DM1 and LGMD and strengthen the interpretation of clinical outcomes
- Characterizing differences in ambulatory status, muscle degeneration patterns and rates of disease progression across patients
